An anti-CGRP antibody partially reduced post-concussion headache sensitivity in mice, with the strongest effects when given before headache triggers during the chronic sensitization phase rather than at the time of injury.
Full prevention of trigger responsesWhile the anti-CGRP antibody only partially reduced headache sensitivity when given at the time of injury, it fully prevented pain responses to headache triggers (CGRP and nitric oxide) during the chronic post-injury phase.
What the researchers found
An anti-CGRP monoclonal antibody partially reduced persistent headache-like sensitivity following mild traumatic brain injury (concussion) in mice. When given before or immediately after repeated head impacts, the antibody partially reduced ongoing tactile hypersensitivity but did not fully prevent it. However, when administered before exposure to headache triggers (CGRP itself or nitric oxide) during the persistent sensitization phase, the antibody fully prevented hypersensitivity. This suggests anti-CGRP therapy may be most effective at blocking the triggers that maintain post-traumatic headache rather than preventing the initial injury response.
Why it matters
Post-traumatic headache (PTH) following concussion is extremely common in military personnel, veterans, and athletes, and can become chronic and debilitating. Current treatments are largely borrowed from migraine therapy without strong evidence. This study provides the first preclinical evidence that the timing of anti-CGRP antibody administration matters critically: the antibody works best not at preventing the initial head-injury response, but at blocking the ongoing triggers that keep pain sensitization alive. This could guide how these drugs are used clinically in concussion patients.
The numbers in context
3 repeated closed head impacts · Partial reduction of periorbital hypersensitivity · Full prevention of trigger-induced hypersensitivity during persistent phase
How the study worked
Researchers used outbred CD1 mice subjected to three repeated closed head impacts to model mild TBI. They tested anti-CGRP monoclonal antibody administration at different timepoints: before injury, immediately after injury, and before headache triggers (CGRP injection or sodium nitroprusside/nitric oxide donor) during the persistent sensitization phase. Periorbital and plantar tactile hypersensitivity were measured as surrogate markers for headache-related pain sensitivity.
Who was studied
Outbred CD1 mice subjected to repeated mild traumatic brain injury (closed head impacts)
What this study cannot tell us
Mouse models of TBI and headache rely on surrogate pain measures (tactile sensitivity) that may not directly correspond to human headache experience. The model uses repeated impacts rather than a single concussion, which may not reflect all clinical scenarios. The study doesn't address whether anti-CGRP treatment would affect cognitive or other post-concussion outcomes. Translation to human TBI timing and dosing requires clinical trials. The antibody used is not specified as any particular clinical anti-CGRP drug.
How to read the evidence
This is a well-designed preclinical animal study using multiple experimental conditions and timing paradigms. The use of both CGRP and nitric oxide triggers strengthens the conclusions. However, it remains a mouse model, and the surrogate pain measures may not directly translate to human headache experience.
When this study was published
Published in 2025, this is a very recent study addressing the growing interest in anti-CGRP therapies for post-traumatic headache — a use case that is actively being explored in clinical trials. The timing insights are immediately relevant to trial design.
The bigger picture
Post-traumatic headache shares many biological features with migraine, including CGRP involvement, which has led to interest in repurposing anti-CGRP drugs for this indication. However, TBI adds layers of complexity — neuroinflammation, blood-brain barrier disruption, and neuronal damage — that don't exist in typical migraine. This study helps parse out when CGRP becomes important in the post-TBI pain process, suggesting it may be more relevant to the maintenance of chronic sensitization than to the acute injury response. This has direct implications for clinical trial design in this population.
Questions still open
- Would anti-CGRP antibodies be effective as a prophylactic treatment for athletes or military personnel at high risk of concussion-related headaches?
- Does the partial acute protection observed mean CGRP plays some role in the initial injury response, or is it simply residual activity against triggers?
- How would these findings translate to clinical trial design — should anti-CGRP drugs be tested as early intervention or as treatment for established post-traumatic headache?
Common questions
Could anti-CGRP migraine drugs help with post-concussion headaches?
Why is CGRP important in post-concussion headaches?
Read the original research
Pretreatment with an anti-CGRP monoclonal antibody attenuates mild TBI-induced tactile hypersensitivity in mice.
The journal of headache and pain, 26(1), 175
Citation
Wattiez, Anne-Sophie; Kuburas, Adisa; Castonguay, William C; Fejgin, Kim; Klewe, Ib V; Russo, Andrew F. (2025). Pretreatment with an anti-CGRP monoclonal antibody attenuates mild TBI-induced tactile hypersensitivity in mice.. The journal of headache and pain, 26(1), 175. https://doi.org/10.1186/s10194-025-02108-x